Association of L-arginine transporters with fodrin: implications for hypoxic inhibition of arginine uptake

被引:50
|
作者
Zharikov, SI
Block, ER
机构
[1] Malcom Randall Dept Vet Affairs Med Ctr, Res Serv 151, Gainesville, FL 32608 USA
[2] Univ Florida, Dept Med, Gainesville, FL 32608 USA
关键词
ankyrin; calpain; hypoxia; pulmonary artery endothelial cells; cationic amino acid transporter-1;
D O I
10.1152/ajplung.2000.278.1.L111
中图分类号
Q4 [生理学];
学科分类号
071003 ;
摘要
In this study, we investigated the possible interaction between the cationic amino acid transporter (CAT)-1 arginine transporter and ankyrin or fodrin. Because ankyrin and fodrin are substrates for calpain and because hypoxia increases calpain expression and activity in pulmonary artery endothelial cells (PAEC), we also studied the effect of hypoxia on ankyrin, fodrin, and CAT-1 contents in PAEC. Exposure to long-term hypoxia (24 h) inhibited L-arginine uptake by PAEC, and this inhibition was prevented by calpain inhibitor 1. The effects of hypoxia and calpain inhibitor 1 were not associated with changes in CAT-1 transporter content in PAEC plasma membranes. However, hypoxia stimulated the hydrolysis of ankyrin and fodrin in PAEC, and this could be prevented by calpain inhibitor 1. Incubation of solubilized plasma membrane proteins with anti-fodrin antibodies resulted in a 70% depletion of CAT-1 immunoreactivity and in a 60% decrease in L-arginine transport activity in reconstituted proteoliposomes (3,291 +/- 117 vs. 8,101 +/- 481 pmol.mg protein(-1).3 min(-1) in control). Incubation with anti-ankyrin antibodies had no effect on CAT-1 content or L-arginine transport in reconstituted proteoliposomes. These results demonstrate that CAT-1 arginine transporters in PAEC are associated with fodrin, but not with ankyrin, and that long-term hypoxia decreases L-arginine transport by a calpain-mediated mechanism that may involve fodrin proteolysis.
引用
收藏
页码:L111 / L117
页数:7
相关论文
共 50 条
  • [21] L-Arginine or agmatine?
    Wohlrab, J
    HAUTARZT, 2004, 55 (07): : 689 - 690
  • [22] The pharmacodynamics of L-arginine
    Boeger, Rainer H.
    JOURNAL OF NUTRITION, 2007, 137 (06): : 1650S - 1655S
  • [23] L-arginine oxalates
    Petrosyan, A. M.
    Sukiasyan, R. P.
    Karapetyan, H. A.
    Antipin, M. Yu.
    Apreyan, R. A.
    JOURNAL OF CRYSTAL GROWTH, 2005, 275 (1-2) : E1927 - E1933
  • [24] Inhibition of SARS-CoV-2 Mpro with Vitamin C, L-Arginine and a Vitamin C/L-Arginine Combination
    Dukic, Ivana
    Kalicanin, Nevena
    Sencanski, Milan
    Pajovic, Snezana B.
    Milicevic, Jelena
    Prljic, Jelena
    Paessler, Slobodan
    Prodanovic, Radivoje
    Glisic, Sanja
    FRONTIERS IN BIOSCIENCE-LANDMARK, 2023, 28 (01):
  • [25] The Pharmacodynamics of L-Arginine
    Boeger, Rainer H.
    ALTERNATIVE THERAPIES IN HEALTH AND MEDICINE, 2014, 20 (03) : 48 - 54
  • [26] L-arginine nitrates
    Terzyan, SS
    Karapetyan, HA
    Sukiasyan, RB
    Petrosyan, AM
    JOURNAL OF MOLECULAR STRUCTURE, 2004, 687 (1-3) : 111 - 117
  • [27] L-arginine and hypertension
    Gokce, N
    JOURNAL OF NUTRITION, 2004, 134 (10): : 2807S - 2811S
  • [28] L-arginine and atherothrombosis
    Loscalzo, J
    JOURNAL OF NUTRITION, 2004, 134 (10): : 2798S - 2800S
  • [29] Inhibition of in vitro pyrraline formation by L-arginine and polyamines
    Méndez, JD
    Leal, LI
    BIOMEDICINE & PHARMACOTHERAPY, 2004, 58 (10) : 598 - 604
  • [30] Inhibition of L-Arginine Metabolizing Enzymes by L-Arginine-Derived Advanced Glycation End Products
    Lai, Ying-Ling
    Aoyama, Sae
    Nagai, Ryoji
    Miyoshi, Noriyuki
    Ohshima, Hiroshi
    JOURNAL OF CLINICAL BIOCHEMISTRY AND NUTRITION, 2010, 46 (02) : 177 - 185